IBM’s new digital platform aims for supply chain ‘visibility’

IBM is collaborating with the National Association of Boards of Pharmacy to build a new digital platform that can bring visibility to the drug supply chain. 

Advertisement

Launching in summer 2023, the platform, dubbed Pulse by NABP, will help manufacturers, wholesalers, pharmacies and regulators “identify counterfeit or substandard prescription medications,” according to a July 27 news release from IBM.

The platform can also connect these entities with each other when required, and provide authorized partners that can help them “accurately trace prescription medications throughout the supply chain.”

The aim of the platform is to give patients more confidence that their prescriptions are legitimate, as well as combat the “gray market” companies in the industry, according to the release.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The hidden cost of lost clinical time and how leading health systems are responding

Friday, August 7
12:00 PM - 1:00 PM CDT

Presenters: Kassaundra McKnight-Young, Zebra TechnologiesGregory Carras, Zebra TechnologiesJennifer Gene, Levata

Advertisement

Next Up in Disruptors

  • OpenAI signed its first international hospital partnership with Ramat Gan, Israel-based Sheba Medical Center. The deal, according to a July…

  • Microsoft is continuing to hire for health tech roles including a forward deployed AI engineer position tied to its healthcare…

  • Amazon is hiring software and applied-science leaders, AI engineers and a healthcare cybersecurity specialist — the kinds of roles hospital…

Advertisement

Comments are closed.